Bio-Techne (TECH) 10-Q 12 Nov 13 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Sep. 30, 2013	Nov. 04, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'TECH	'
Entity Registrant Name	'TECHNE CORP /MN/	'
Entity Central Index Key	'0000842023	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	36,865,781

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Earnings and Comprehensive Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Net sales	$85,668	$75,025
Cost of sales	24,554	19,442
Gross margin	61,114	55,583
Operating expenses:	'	'
Selling, general and administrative	14,021	10,328
Research and development	7,702	7,452
Total operating expenses	21,723	17,780
Operating income	39,391	37,803
Other income (expense):	'	'
Interest income	567	661
Other non-operating expense, net	-304	-478
Total other income (expense)	263	183
Earnings before income taxes	39,654	37,986
Income taxes	12,226	12,318
Net earnings	27,428	25,668
Other comprehensive income (loss):	'	'
Foreign currency translation adjustments	7,902	3,925
Unrealized losses on available-for-sale investments, net of tax of ($17,396) and ($7,589), respectively	-36,776	-13,559
Other comprehensive loss	-28,874	-9,634
Comprehensive (loss) income	($1,446)	$16,034
Earnings per share:	'	'
Basic	$0.74	$0.70
Diluted	$0.74	$0.70
Cash dividends per common share:	$0.30	$0.28
Weighted average common shares outstanding:	'	'
Basic	36,842	36,828
Diluted	36,928	36,895

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Earnings and Comprehensive Income (Parenthetical) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Unrealized losses on available-for-sale investments, tax	($17,396)	($7,589)

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$83,856	$163,786
Short-term available-for-sale investments	100,843	169,151
Trade accounts receivable, less allowance for doubtful accounts of $467 and $428, respectively	42,240	38,183
Other receivables	1,928	1,992
Deferred income taxes	9,527	0
Inventories	39,957	34,877
Prepaid expenses	2,285	1,527
Total current assets	280,636	409,516
Available-for-sale investments	138,477	132,376
Property and equipment, net	113,362	108,756
Goodwill	143,800	84,336
Intangible assets, net	100,523	40,552
Other assets	2,492	2,562
Assets, Total	779,290	778,098
Current liabilities:	'	'
Trade accounts payable	6,656	6,236
Salaries, wages and related accruals	6,409	4,025
Accrued expenses	4,242	9,603
Income taxes payable	2,969	2,276
Deferred income taxes	0	9,944
Total current liabilities	20,276	32,084
Deferred income taxes	32,251	8,473
Shareholders' equity:	'	'
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 36,852,781 and 36,834,678, respectively	369	368
Additional paid-in capital	136,613	134,895
Retained earnings	604,102	587,725
Accumulated other comprehensive income	-14,321	14,553
Total shareholders' equity	726,763	737,541
Liabilities and Equity, Total	$779,290	$778,098

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, except Share data, unless otherwise specified
Trade accounts receivable, allowance for doubtful accounts	$467	$428
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	36,852,781	36,834,678
Common stock, shares outstanding	36,852,781	36,834,678

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net earnings	$27,428	$25,668
Adjustments to reconcile net earnings to net cash provided by operating activities:	'	'
Depreciation and amortization	4,090	3,105
Costs recognized on sale of acquired inventory	1,731	1,264
Deferred income taxes	-1,329	-777
Stock-based compensation expense	569	303
Excess tax benefit from stock option exercises	-4	-1
Losses by equity method investees	0	41
Other	124	107
Change in operating assets and operating liabilities, net of acquisition:	'	'
Trade accounts and other receivables	-106	1,053
Inventories	-296	-1,084
Prepaid expenses	-305	-252
Trade accounts payable and accrued expenses	-828	218
Salaries, wages and related accruals	1,420	400
Income taxes payable	91	-782
Net cash provided by operating activities	32,585	29,263
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Acquisition, net of cash acquired	-103,049	0
Purchase of available-for-sale investments	-27,010	-21,119
Proceeds from sales of available-for-sale investments	12,700	6,200
Proceeds from maturities of available-for-sale investments	16,090	11,601
Additions to property and equipment	-3,811	-2,515
Distribution from unconsolidated entity	85	0
Increase in other long-term assets	-138	-87
Net cash used in investing activities	-105,133	-5,920
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Cash dividends	-11,051	-10,312
Proceeds from stock option exercises	1,145	136
Excess tax benefit from stock option exercises	4	1
Purchase of common stock for stock bonus plans	0	-573
Net cash used in financing activities	-9,902	-10,748
Effect of exchange rate changes on cash and cash equivalents	2,520	1,535
Net increase in cash and cash equivalents	-79,930	14,130
Cash and cash equivalents at beginning of period	163,786	116,675
Cash and cash equivalents at end of period	$83,856	$130,805

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Sep. 30, 2013
Basis of Presentation	'
	A. Basis of Presentation:
	The interim unaudited condensed consolidated financial statements of Techne Corporation and Subsidiaries (the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. The accompanying interim unaudited condensed consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.
	A summary of significant accounting policies followed by the Company is detailed in the Company’s Annual Report on Form 10-K for fiscal 2013. The Company follows these policies in preparation of the interim unaudited condensed consolidated financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2013, included in the Company’s Annual Report on Form 10-K for fiscal 2013.

Acquisition

Acquisition	3 Months Ended
	Sep. 30, 2013
Acquisition	'
	B. Acquisition
	On July 22, 2013, the Company’s R&D Systems subsidiary acquired for cash all of the outstanding shares of Bionostics Holdings, Ltd. (Bionostics) and its U.S. operating subsidiary, Bionostics, Inc. Bionostics is a global leader in the development, manufacture and distribution of control solutions that verify the proper operation of in-vitro diagnostic devices primarily utilized in point of care blood glucose and blood gas testing. Bionostics is included in the Company’s Clinical Controls segment.
	In connection with the Bionostics acquisition, the Company recorded $14.4 million of developed technology intangible assets that have an estimated useful life of 9 years, $2.7 million of trade name intangible assets that have an estimated useful life of 5 years, $2.4 million related to non-compete agreements that have an estimated useful life of 3 years, and $41.0 million related to customer relationships that have an estimated useful life of 14 years. The intangible asset amortization is not deductible for income tax purposes.
	The goodwill recorded as a result of the Bionostics acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration from future products and customers. The goodwill is not deductible for income tax purposes.
	Transaction costs of $532,000 and $607,000 were included in the Company’s selling, general and administrative costs during the quarters ended September 30, 2013 and June 30, 2013.
	The aggregate purchase price of the acquisition was allocated to the assets acquired and liabilities assumed based on their preliminarily estimated fair values at the date of acquisition. The preliminary estimate of the excess of purchase price over the fair value of net tangible assets acquired was allocated to identifiable intangible assets and goodwill. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the Bionostics acquisition (in thousands):
	Current assets	$	9,605
	Intangible Assets		60,500
	Goodwill		56,804
	Equipment		2,180
	Total assets acquired		129,089
	Liabilities		3,777
	Deferred income taxes		22,263
	Net assets acquired	$	103,049
	Cash paid, net of cash acquired	$	103,049
	Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of acquisition based on management’s assessment. The purchase price allocated to developed technology, trade names, non-compete agreements and customer relationships was based on management’s forecasted cash inflows and outflows and using a relief-from-royalty and a multi-period excess earnings method to calculate the fair value of assets purchased. The developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Amortization expense related to trade names, the non-compete agreement and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The deferred income tax liability represents the estimated future impact of adjustments for the cost to be recognized upon the sale of acquired inventory that was written up to fair value and intangible asset amortization, both of which are not deductible for income tax purposes.
	The Company’s condensed consolidated financial statements include, from the date of acquisition, Bionostics net sales of $6.2 million and a net loss of $16,000. Bionostics net loss for the quarter ended September 30, 2013 included amortization of intangibles of $1.1 million and $660,000 costs recognized on the sales of acquired inventory.

AvailableForSale_Investments

Available-For-Sale Investments	3 Months Ended
	Sep. 30, 2013
Available-For-Sale Investments	'
	C. Available-For-Sale Investments:
	The Company’s available-for-sale securities are carried at fair value using Level 1 and Level 2 inputs. The fair value of the Company’s available-for-sale investments at September 30, 2013 and June 30, 2013 were $239 million and $302 million, respectively. The amortized cost basis of the Company’s available-for-sale investments at September 30, 2013 and June 30, 2013 were $233 million and $241 million, respectively.
	Included in the Company’s available-for-sale securities is an investment in the common stock and warrants of ChemoCentryx (CCXI). The fair value of the Company’s investment was $35.2 million and $89.6 million at September 30, 2013 and June 30, 2013, respectively. The cost basis of the Company’s investment in CCXI was $29.5 million at both September 30, 2013 and June 30, 2013.

Inventories

Inventories	3 Months Ended
	Sep. 30, 2013
Inventories	'
	D. Inventories:
	Inventories consist of (in thousands):
		September 30,		June 30,
		2013		2013
	Raw materials	$	8,373	$	5,885
	Finished goods		31,584		28,992
		$	39,957	$	34,877

Property_and_Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2013
Property and Equipment	'
	E. Property and Equipment:
	Property and equipment consist of (in thousands):
		September 30,			June 30,
		2013			2013
	Cost:
	Land	$	7,506		$	7,438
	Buildings and improvements		146,252			142,656
	Machinery and equipment		47,355			39,706
			201,113			189,800
	Accumulated depreciation and amortization		(87,751	)		(81,044	)
		$	113,362		$	108,756

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Sep. 30, 2013
Intangible Assets and Goodwill	'
	F. Intangible Assets and Goodwill:
	Intangible assets and goodwill consist of (in thousands):
		September 30,			June 30,
		2013			2013
	Developed technology	$	44,546		$	28,656
	Trade names		20,779			17,659
	Customer relationships		49,808			8,613
	Non-compete agreement		2,800			400
			117,933			55,328
	Accumulated amortization		(17,410	)		(14,776	)
		$	100,523		$	40,552
	Goodwill	$	143,800		$	84,336
	Changes to the carrying amount of net intangible assets for the quarter ended September 30, 2013 consists of (in thousands):
	Beginning balance	$	40,552
	Acquisition		60,500
	Amortization expense		(2,188	)
	Currency translation		1,659
	Ending balance	$	100,523
	The estimated future amortization expense for intangible assets as of September 30, 2013 is as follows (in thousands):
	Period Ending June 30:
	2014	$	7,761
	2015		10,348
	2016		10,328
	2017		9,519
	2018		9,468
	Thereafter		53,099
		$	100,523
	The change in the carrying amount of goodwill for the quarter ended September 30, 2013 resulted from the Bionostics acquisition and currency translation.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Sep. 30, 2013
Earnings Per Share	'
	G. Earnings Per Share:
	Shares used in the earnings per share computations are as follows (in thousands):
		Quarter Ended
		September 30,
		2013		2012
	Weighted average common shares outstanding-basic		36,842		36,828
	Dilutive effect of stock options		86		67
	Weighted average common shares outstanding-diluted		36,928		36,895
	The dilutive effect of stock options in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 223,000 and 199,000 for the quarters ended September 30, 2013 and 2012, respectively.

Segment_Information

Segment Information	3 Months Ended
	Sep. 30, 2013
Segment Information	'
	H. Segment Information:
	The Company has two reportable segments based on the nature of products (biotechnology and clinical controls). Following is financial information relating to the Company’s reportable segments (in thousands):
		Quarter Ended
		September 30,
		2013			2012
	External sales
	Biotechnology	$	73,190		$	69,503
	Clinical Controls		12,478			5,522
	Consolidated net sales	$	85,668		$	75,025
	Earnings before income taxes
	Biotechnology	$	39,378		$	36,994
	Clinical Controls		2,285			2,103
	Segment earnings before income taxes		41,663			39,097
	Unallocated corporate expenses and equity method investee losses		(2,009	)		(1,111	)
	Consolidated earnings before income taxes	$	39,654		$	37,986

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income	'
	I. Accumulated Other Comprehensive Income:
	Accumulated other comprehensive income (loss) consists of (in thousands):
		September 30,			June 30,
		2013			2013
	Foreign currency translation adjustments	$	(16,379	)	$	(24,281	)
	Net unrealized gain on available-for-sale investments, net of tax		2,058			38,834
		$	(14,321	)	$	14,553

Acquisition_Tables

Acquisition (Tables)	3 Months Ended
	Sep. 30, 2013
Estimated Fair Values of Assets Acquired and Liabilities Assumed	'
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the Bionostics acquisition (in thousands):
	Current assets	$	9,605
	Intangible Assets		60,500
	Goodwill		56,804
	Equipment		2,180
	Total assets acquired		129,089
	Liabilities		3,777
	Deferred income taxes		22,263
	Net assets acquired	$	103,049
	Cash paid, net of cash acquired	$	103,049

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Sep. 30, 2013
Inventories	'
	Inventories consist of (in thousands):
		September 30,		June 30,
		2013		2013
	Raw materials	$	8,373	$	5,885
	Finished goods		31,584		28,992
		$	39,957	$	34,877

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2013
Property and Equipment	'
	Property and equipment consist of (in thousands):
		September 30,			June 30,
		2013			2013
	Cost:
	Land	$	7,506		$	7,438
	Buildings and improvements		146,252			142,656
	Machinery and equipment		47,355			39,706
			201,113			189,800
	Accumulated depreciation and amortization		(87,751	)		(81,044	)
		$	113,362		$	108,756

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Sep. 30, 2013
Intangible Assets	'
	Intangible assets and goodwill consist of (in thousands):
		September 30,			June 30,
		2013			2013
	Developed technology	$	44,546		$	28,656
	Trade names		20,779			17,659
	Customer relationships		49,808			8,613
	Non-compete agreement		2,800			400
			117,933			55,328
	Accumulated amortization		(17,410	)		(14,776	)
		$	100,523		$	40,552
	Goodwill	$	143,800		$	84,336
Changes in Carrying Amount of Goodwill	'
	Changes to the carrying amount of net intangible assets for the quarter ended September 30, 2013 consists of (in thousands):
	Beginning balance	$	40,552
	Acquisition		60,500
	Amortization expense		(2,188	)
	Currency translation		1,659
	Ending balance	$	100,523
Estimated Future Amortization Expense for Intangible Assets	'
	The estimated future amortization expense for intangible assets as of September 30, 2013 is as follows (in thousands):
	Period Ending June 30:
	2014	$	7,761
	2015		10,348
	2016		10,328
	2017		9,519
	2018		9,468
	Thereafter		53,099
		$	100,523

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2013
Earnings per Share	'
	Shares used in the earnings per share computations are as follows (in thousands):
		Quarter Ended
		September 30,
		2013		2012
	Weighted average common shares outstanding-basic		36,842		36,828
	Dilutive effect of stock options		86		67
	Weighted average common shares outstanding-diluted		36,928		36,895

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2013
Financial Information Relating to Reportable Segments	'
	Following is financial information relating to the Company’s reportable segments (in thousands):
		Quarter Ended
		September 30,
		2013			2012
	External sales
	Biotechnology	$	73,190		$	69,503
	Clinical Controls		12,478			5,522
	Consolidated net sales	$	85,668		$	75,025
	Earnings before income taxes
	Biotechnology	$	39,378		$	36,994
	Clinical Controls		2,285			2,103
	Segment earnings before income taxes		41,663			39,097
	Unallocated corporate expenses and equity method investee losses		(2,009	)		(1,111	)
	Consolidated earnings before income taxes	$	39,654		$	37,986

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss)	'
	Accumulated other comprehensive income (loss) consists of (in thousands):
		September 30,			June 30,
		2013			2013
	Foreign currency translation adjustments	$	(16,379	)	$	(24,281	)
	Net unrealized gain on available-for-sale investments, net of tax		2,058			38,834
		$	(14,321	)	$	14,553

Acquisition_Additional_Informa

Acquisition - Additional Information (Detail) (USD $)	3 Months Ended				1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Jun. 30, 2013	Jul. 22, 2013	Jul. 22, 2013	Jul. 22, 2013	Jul. 22, 2013
			Bionostics Holdings, Ltd	Bionostics Holdings, Ltd	Bionostics Holdings, Ltd	Bionostics Holdings, Ltd	Bionostics Holdings, Ltd	Bionostics Holdings, Ltd
					Developed technology	Trade names	Non-compete agreement	Customer relationships
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Acquired intangible assets	'	'	'	'	$14,400,000	$2,700,000	$2,400,000	$41,000,000
Acquired intangible assets, useful life (in years)	'	'	'	'	'9 years	'5 years	'3 years	'14 years
Business acquisition, transaction costs	'	'	532,000	607,000	'	'	'	'
Net Sales	'	'	6,200,000	'	'	'	'	'
Net Loss	'	'	-16,000	'	'	'	'	'
Amortization of intangible assets	'	'	1,100,000	'	'	'	'	'
Costs recognized on sales of acquired inventory	$1,731,000	$1,264,000	$660,000	'	'	'	'	'

Estimated_Fair_Values_of_Asset

Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) (USD $)	3 Months Ended			1 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2013	Jul. 22, 2013
				Bionostics Holdings, Ltd
Business Acquisition [Line Items]	'	'	'	'
Current assets	'	'	'	$9,605
Intangible Assets	'	'	'	60,500
Goodwill	143,800	'	84,336	56,804
Equipment	'	'	'	2,180
Total assets acquired	'	'	'	129,089
Liabilities	'	'	'	3,777
Deferred income taxes	'	'	'	22,263
Net assets acquired	'	'	'	103,049
Cash paid, net of cash acquired	$103,049	$0	'	$103,049

AvailableForSaleInvestments_Ad

Available-For-Sale-Investments - Additional Information (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Millions, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, fair value	$239	$302
Available-for-sale securities, amortized cost	233	241
Chemo Centryx, Inc.	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Available-for-sale securities, fair value	35.2	89.6
Available-for-sale securities, amortized cost	$29.50	$29.50

Inventories_Detail

Inventories (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Raw materials	$8,373	$5,885
Finished goods	31,584	28,992
Inventories	$39,957	$34,877

Property_and_Equipment_Detail

Property and Equipment (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Cost:	'	'
Land	$7,506	$7,438
Buildings and improvements	146,252	142,656
Machinery and equipment	47,355	39,706
Property, Plant and Equipment, Gross, Total	201,113	189,800
Accumulated depreciation and amortization	-87,751	-81,044
Property and equipment, net	$113,362	$108,756

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Developed technology	$44,546	$28,656
Trade names	20,779	17,659
Customer relationships	49,808	8,613
Non-compete agreement	2,800	400
Finite-Lived Intangible Assets, Gross, Total	117,933	55,328
Accumulated amortization	-17,410	-14,776
Intangible assets, net	100,523	40,552
Goodwill	$143,800	$84,336

Changes_in_Carrying_Amount_of_

Changes in Carrying Amount of Net Intangible Assets (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Intangible Assets [Line Items]	'
Beginning balance	$40,552
Acquisition	60,500
Amortization expense	-2,188
Currency translation	1,659
Ending balance	$100,523

Estimated_Future_Amortization_

Estimated Future Amortization Expense for Intangible Assets (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Expected Amortization Expense [Line Items]	'	'
2014	$7,761	'
2015	10,348	'
2016	10,328	'
2017	9,519	'
2018	9,468	'
Thereafter	53,099	'
Intangible assets, net	$100,523	$40,552

Earnings_Per_Share_Detail

Earnings Per Share (Detail)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share Disclosure [Line Items]	'	'
Weighted average common shares outstanding-basic	36,842	36,828
Dilutive effect of stock options	86	67
Weighted average common shares outstanding-diluted	36,928	36,895

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share Disclosure [Line Items]	'	'
Number of potentially dilutive stock option shares excluded from the calculation of earnings per share	223,000	199,000

Segment_Information_Additional

Segment Information - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2013
	Segment
Segment Reporting Information [Line Items]	'
Number of reportable segments	2

Financial_Information_Relating

Financial Information Relating to Reportable Segments (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'
External sales	$85,668	$75,025
Earnings before income taxes	39,654	37,986
Reportable Segment	'	'
Segment Reporting Information [Line Items]	'	'
External sales	85,668	75,025
Earnings before income taxes	41,663	39,097
Reportable Segment | Biotechnology	'	'
Segment Reporting Information [Line Items]	'	'
External sales	73,190	69,503
Earnings before income taxes	39,378	36,994
Reportable Segment | Clinical Controls	'	'
Segment Reporting Information [Line Items]	'	'
External sales	12,478	5,522
Earnings before income taxes	2,285	2,103
Unallocated Amount to Segment	'	'
Segment Reporting Information [Line Items]	'	'
Earnings before income taxes	($2,009)	($1,111)

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Detail) (USD $)	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'
Foreign currency translation adjustments	($16,379)	($24,281)
Net unrealized gain on available-for-sale investments, net of tax	2,058	38,834
Accumulated other comprehensive income	($14,321)	$14,553